Design and Preclinical Evaluation of Two Prostate-Specific Membrane Antigen-Targeting Trifluoroborate Derivatives Suitable for One-Step Radiofluorination
6 affiliations
- 1University of Helsinki , , ,
- 2University of Turku and Turku University Hospital , , ,
- 3University of Turku , , ,
- 4Johannes Kepler University Linz , , ,
- 5Samo University , ,
- 6Helsinki University Hospital and University of Helsinki , , ,
Abstract
Prostate cancer was the most frequently diagnosed cancer and the second leading cause of cancer-related death among men in the United States in 2025. Prostate-specific membrane antigen (PSMA)-targeted PET tracers have significantly improved the detection, visualization, and staging of prostate cancer. Recently, the novel prosthetic group [18F]AmBF3-Tz was introduced, combining simple isotopic 18F-radiolabeling of alkylammoniomethyltrifluoroborates (AmBF3) with efficient bioorthogonal tetrazine-trans-cyclooctene (TCO) conjugation. This study evaluated the suitability of [18F]AmBF3-Tz for radiolabeling PSMA-targeting urea derivatives and assessed its impact on PSMA-binding affinity in vitro and in vivo. Four precursors─TCO-PSMA, TCO-tranexamic acid-PSMA, AmBF3-PSMA, and AmBF3-tranexamic acid-PSMA─were synthesized and used for the preparation of [18F]AmBF3-PSMA and [18F]AmBF3-tranexamic acid-PSMA via one-step or two-step labeling strategies. Conjugation before radiolabeling gave radiochemical yields of 5.2–11.8%, whereas the two-step method gave 0.7–9.8%. Although these yields demonstrate feasibility, they are lower and more variable than the 33 ± 5% yield obtained for [18F]AmBF3-Tz and would require substantial optimization before clinical translation. Overall, [18F]AmBF3-PSMA and [18F]AmBF3-tranexamic acid-PSMA demonstrated PSMA-specific tumor uptake and enabled the visualization of C4-2 xenografts. The tranexamic acid-containing tracer showed higher tumor-to-background ratios than [18F]AmBF3-PSMA in this study, but the absolute tumor uptake was not significantly different between the two tracers. The moderate and variable radiochemical yields, microscale reaction sensitivity, and small animal group sizes indicate that this proof-of-concept platform warrants further optimization before its suitability for clinical translation can be assessed.
Related
- Discovery and preclinical evaluation of ZLC853 as a potential clinical candidate covalently targeting CDK12/13 kinases
- 618 A novel preclinical mouse model to investigate IL-18-targeting therapies
- 882 BCG040, a novel B7-H4-targeting biparatopic ADC, demonstrates superior preclinical efficacy in heterogeneous tumors
- 401 genO-hCCR8/hCCL1/hFcγR preclinical mouse model for efficacy assessment of CCR8-targeting agents
- Re-Evaluating Multi-Kinase Inhibitors Targeting FGFR and VEGFR Pathways for Combined Therapy in Colorectal Cancer: A Preclinical Study
BibTeX
@article{paulus2026design,
title = {{Design and Preclinical Evaluation of Two Prostate-Specific Membrane Antigen-Targeting Trifluoroborate Derivatives Suitable for One-Step Radiofluorination}},
author = {Andreas Paulus and Sofia Otaru and Risto Savela and Surachet Imlimthan and Tatsiana Auchynnikava and Dominika Novotná and Anisa Biti and Mirkka Sarparanta and Heidi Liljenbäck and Tatu Martinmäki and Alexander Popkov and Kim A. Bergström and Anne Roivainen and Anu J. Airaksinen},
journal = {ACS Omega},
year = {2026},
month = oct,
doi = {10.1021/acsomega.6c08595},
url = {https://pubs.acs.org/acsodf/article/doi/10.1021/acsomega.6c08595/5454643/Design-and-Preclinical-Evaluation-of-Two-Prostate},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Design and Preclinical Evaluation of Two Prostate-Specific Membrane Antigen-Targeting Trifluoroborate Derivatives Suitable for One-Step Radiofluorination
AU - Andreas Paulus
AU - Sofia Otaru
AU - Risto Savela
AU - Surachet Imlimthan
AU - Tatsiana Auchynnikava
AU - Dominika Novotná
AU - Anisa Biti
AU - Mirkka Sarparanta
AU - Heidi Liljenbäck
AU - Tatu Martinmäki
AU - Alexander Popkov
AU - Kim A. Bergström
AU - Anne Roivainen
AU - Anu J. Airaksinen
PY - 2026
DA - 2026/10/20
JO - ACS Omega
DO - 10.1021/acsomega.6c08595
UR - https://pubs.acs.org/acsodf/article/doi/10.1021/acsomega.6c08595/5454643/Design-and-Preclinical-Evaluation-of-Two-Prostate
AB - Prostate cancer was the most frequently diagnosed cancer and the second leading cause of cancer-related death among men in the United States in 2025. Prostate-specific membrane antigen (PSMA)-targeted PET tracers have significantly improved the detection, visualization, and staging of prostate cancer. Recently, the novel prosthetic group [18F]AmBF3-Tz was introduced, combining simple isotopic 18F-radiolabeling of alkylammoniomethyltrifluoroborates (AmBF3) with efficient bioorthogonal tetrazine-trans-cyclooctene (TCO) conjugation. This study evaluated the suitability of [18F]AmBF3-Tz for radiolabeling PSMA-targeting urea derivatives and assessed its impact on PSMA-binding affinity in vitro and in vivo. Four precursors─TCO-PSMA, TCO-tranexamic acid-PSMA, AmBF3-PSMA, and AmBF3-tranexamic acid-PSMA─were synthesized and used for the preparation of [18F]AmBF3-PSMA and [18F]AmBF3-tranexamic acid-PSMA via one-step or two-step labeling strategies. Conjugation before radiolabeling gave radiochemical yields of 5.2–11.8%, whereas the two-step method gave 0.7–9.8%. Although these yields demonstrate feasibility, they are lower and more variable than the 33 ± 5% yield obtained for [18F]AmBF3-Tz and would require substantial optimization before clinical translation. Overall, [18F]AmBF3-PSMA and [18F]AmBF3-tranexamic acid-PSMA demonstrated PSMA-specific tumor uptake and enabled the visualization of C4-2 xenografts. The tranexamic acid-containing tracer showed higher tumor-to-background ratios than [18F]AmBF3-PSMA in this study, but the absolute tumor uptake was not significantly different between the two tracers. The moderate and variable radiochemical yields, microscale reaction sensitivity, and small animal group sizes indicate that this proof-of-concept platform warrants further optimization before its suitability for clinical translation can be assessed.
SN - 2470-1343
ER -